The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study GS-US-384-1943.
View study details on ClinicalTrials.gov
Subjects 18 to 70 y/o with a liver biopsy consistent with NASH and bridging (F3 fibrosis) according to the NASH CRN classification in the opinion of the central reader.
June 01, 2018